Veerhealth Care Files Q4 Compliance, Reports Zero Share Dematerialization

SEBIEXCHANGE
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
Veerhealth Care Files Q4 Compliance, Reports Zero Share Dematerialization
Overview

Veerhealth Care Ltd. has submitted its quarterly compliance certificate for the period ending March 31, 2026, as per SEBI Regulation 74(5). The Registrar and Share Transfer Agent confirmed that no share certificates were dematerialized during this quarter, indicating the company's adherence to regulatory requirements for share transfers.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Veerhealth Care Files Q4 Compliance Certificate

Veerhealth Care Ltd. has submitted its mandatory compliance certificate for the fourth quarter of fiscal year 2026, ending March 31, 2026. The filing, made under SEBI Regulation 74(5), confirms with its Registrar and Share Transfer Agent that no physical share certificates were converted into dematerialized form during this period.

Why This Filing Matters

This routine disclosure is mandated by SEBI Regulation 74(5) for all listed entities. It requires companies to provide a quarterly certificate from their Registrar and Share Transfer Agent (RTA) verifying the status of security dematerialization. This process ensures companies adhere to SEBI's directives on dematerialization and maintain accurate shareholding records, promoting transparency for investors.

Company Background

Veerhealth Care Ltd. was originally incorporated in 1992 as Niyati Leasing Limited. The company diversified into pharmaceuticals in 2013 and cosmetic manufacturing in 2020. It is listed on the Bombay Stock Exchange (BSE) and operates in the Ayurvedic medicines and personal care markets.

Past Regulatory Note

The company has had prior interactions with regulatory bodies. Notably, in 2017, the Securities Appellate Tribunal (SAT) overturned a penalty order from SEBI concerning an issue previously decided in the company's favor.

Recent Corporate Activity

Veerhealth Care has been active in corporate finance matters. Board meetings held in March 2026 considered significant proposals, including the potential issuance of convertible warrants valued up to Rs. 21 crore, which would be subject to shareholder and regulatory approvals.

Current Status and Implications

This filing reaffirms Veerhealth Care's commitment to its statutory obligations regarding shareholding records. The reported zero dematerialization indicates a stable period with no active requests for converting physical shares to electronic form. The company continues to operate within the established regulatory framework for listed entities in India.

Industry Compliance

While this specific metric is unique to each company's share activity, many listed companies, including peers like ICRA Limited and BLS E-Services Limited, regularly submit similar certificates, reflecting industry-wide adherence to SEBI Regulation 74(5).

Looking Ahead

Investors will continue to monitor future quarterly compliance certificates for ongoing adherence to SEBI regulations. Key areas of interest also include the progress and outcomes of Veerhealth Care's proposed fund-raising initiatives, specifically the issuance of convertible warrants, as well as any further operational or corporate announcements concerning its pharmaceutical and cosmetic segments.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.